JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dandiya, P. C.
Right arrow Articles by Sellers, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dandiya, P. C.
Right arrow Articles by Sellers, E. A.
Journal of Pharmacology And Experimental Therapeutics, Vol. 126, Issue 4, 334-337, 1959
Copyright © 1959 by American Society for Pharmacology and Experimental Therapeutics


STUDIES ON ACORUS CALAMUS (IV): INVESTIGATIONS ON MECHANISM OF ACTION IN MICE

P. C. Dandiya 1, H. Cullumbine 1, and E. A. Sellers 1

1 Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Canada

Pretreatment of mice with lysergic acid diethylamide partly prevents the hypnotic potentiating action of Acorns oil.

In iproniazid-treated mice, Acorus oil causes a fair degree of stimulation instead of sedation, noticed in untreated mice.

The hypnotic potentiating action of Acorus oil is not a result of its hypothermic action. Reserpine does not prolong pentobarbital sleeping time, if the body temperature is not allowed to fall. The hypothermic action of chlorpromazine is only partly responsible for its hypnotic potentiating action.

Submitted on April 7, 1959







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1959 by the American Society for Pharmacology and Experimental Therapeutics.